
NewsABC7 News San Francisco (KGO-TV)October 29, 2026San Francisco County
Eli Lilly reports clinical trial results for weight loss drug retatrutide
Photo: ABC7 News San Francisco (KGO-TV)
Eli Lilly announced clinical trial results showing its weekly injection retatrutide achieved more than double the weight loss of Ozempic over 80 weeks in adults with type 2 diabetes. The company plans to submit the drug for FDA approval in early 2027.
Read the full story at ABC7 News San Francisco (KGO-TV)Why It Matters
A potential new prescription medication could soon expand treatment options for weight management and type 2 diabetes, pending regulatory review.
Key Facts
- Eli Lilly shared phase 3 clinical trial results for retatrutide involving more than 1,000 adults with type 2 diabetes.
- Participants taking retatrutide lost an average of 44.3 lbs on the 9mg dose and 47.4 lbs on the 12mg dose over 80 weeks.
- Participants taking the highest Ozempic 2mg dose lost an average of 20.9 lbs over the same 80-week period.
- Retatrutide is a once-weekly injection that mimics three hunger-regulating hormones: GLP-1, GIP, and glucagon.
- Retatrutide lowered A1C by 2.2% compared to 1.8% with Ozempic.
- Eli Lilly plans to submit retatrutide for FDA approval in early 2027.
- Novo Nordisk expects FDA approval for its experimental drug CagriSema by the end of the year.
- Neither retatrutide nor CagriSema are currently FDA approved.
Who's Mentioned
otherCagriSema“Experimental drug by Novo Nordisk”otherZepbound“Medication approved to treat overweight and obesity”otherOzempic“Type 2 diabetes medication made by Novo Nordisk used as a comparator in clinical”OrganizationNational Institutes of Health“Provided information on GLP-1 hormone effects”otherWegovy“Medication approved to treat overweight and obesity”OrganizationEli Lilly“Manufacturer of retatrutide, Mounjaro, and Zepbound”otherMounjaro“Medication approved to treat type 2 diabetes”otherRetatrutide“Next-generation weight loss drug developed by Eli Lilly”OrganizationU.S. Food and Drug Administration“Regulatory agency responsible for drug approvals”OrganizationNovo Nordisk“Manufacturer of Ozempic, Wegovy, and CagriSema”
